Gastrointestinal delivery of anti-inflammatory nanoparticles.

Authors:
Address: Department of Biology, Center for Diagnostics and Therapeutics, Georgia State University, Atlanta, Georgia, USA.
Journal:


Publication:

abstract

The concept of nanomedicine has risen to be the future of medicine. Advantages of using nanoobjects as vectors for drug delivery systems are numerous, such as fewer side effects due to a low drug dose, and high specificity between drug and target. Unlike systemic therapy, targeting a specific target is more efficient and less costly. In inflammatory bowel disease, including ulcerative colitis and Crohn disease, the colon represents the targeted organ. A large number of drugs are candidates for loading into nanoparticles (NPs). Small molecules, such as tripeptides and siRNA, or larger molecules, such as proteins (hormones, antibodies (Ab), etc.), can be encapsulated alone or in a complex form inside the NPs. In our studies, once NPs are synthesized and loaded with anti-inflammatory compounds, they are delivered to the colon. An efficient technique has been developed for specific NP targeting to digestive tract regions, including the colon, using a hydrogel based on electrostatic interactions between positive ions and negative polysaccharides. An in situ double cross-linking process, mediated by Ca²⁺ and SO₄²⁻, of chitosan and alginate administered to the mouse Gastrointestinal (GI) tract by double gavage, is used for gel formation. When the drug is given in NPs, NPs are targeted to the colon, and NP degradation by aggressive environmental conditions in the GI tract is significantly reduced. Using a biomaterial (hydrogel) associated with nanotechnology, lower doses of drug can be loaded efficiently and delivered to the colon to reduce colonic inflammation.

Copyright © 2012 Elsevier Inc. All rights reserved.



Related Articles
Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model.
Gastroenterology. 2010
Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model.
Laroui H, Dalmasso G, Nguyen HT, Yan Y, Sitaraman SV, Merlin D. Gastroenterology. 2010 Mar; 138(3):843-53.e1-2. Epub 2009 Nov 10.
A novel pH-sensitive hydrogel composed of N,O-carboxymethyl chitosan and alginate cross-linked by genipin for protein drug delivery.
J Control Release. 2004
A novel pH-sensitive hydrogel composed of N,O-carboxymethyl chitosan and alginate cross-linked by genipin for protein drug delivery.
Chen SC, Wu YC, Mi FL, Lin YH, Yu LC, Sung HW. J Control Release. 2004 Apr 28; 96(2):285-300.
Coated chitosan pellets containing rutin intended for the treatment of inflammatory bowel disease: in vitro characteristics and in vivo evaluation.
Int J Pharm. 2012
Coated chitosan pellets containing rutin intended for the treatment of inflammatory bowel disease: in vitro characteristics and in vivo evaluation.
Rabišková M, Bautzová T, Gajdziok J, Dvořáčková K, Lamprecht A, Pellequer Y, Spilková J. Int J Pharm. 2012 Jan 17; 422(1-2):151-9. Epub 2011 Nov 3.
Review Pharmaceutical approaches to colon targeted drug delivery systems.
J Pharm Pharm Sci. 2003
Review Pharmaceutical approaches to colon targeted drug delivery systems.
Chourasia MK, Jain SK. J Pharm Pharm Sci. 2003 Jan-Apr; 6(1):33-66.
Review Phase transition system: novel oral in-situ gel.
Curr Drug Deliv. 2008
Review Phase transition system: novel oral in-situ gel.
Nagarwal RC, Pandit JK. Curr Drug Deliv. 2008 Oct; 5(4):282-9.

To top Home


Show map | Diseases | Vaccination | Chronic disease | Medicine | Pregnancy | Heat & Sunburn | Cold | Security | Useful tips | Faq | News

TraveldoctorOnline 2001 • Disclaimer webmaster

The contents within traveldoctoronline are presented only for informational purposes and cannot substitute for professional health care or any other medical treatment.All users of this website with health problems should be oblige always to consult their medical doctor before starting any treatment.